Generation of iPSC lines from archived non-cryoprotected biobanked dura mater

• Published in: Acta neuropathologica communications Vol. 2; no. 1; p. 4
• Main Authors: Sproul, Andrew A, Vensand, Lauren B, Dusenberry, Carmen R, Jacob, Samson, Vonsattel, Jean Paul G, Paull, Daniel J, Shelanski, Michael L, Crary, John F, Noggle, Scott A
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07.01.2014; BioMed Central
• Subjects: Alzheimer Disease - pathology; Animals; Antigens, Surface - metabolism; Cell Differentiation; Cell Line, Transformed - pathology; Cell Proliferation; Databases as Topic; Dura Mater - pathology; Fibroblasts - metabolism; Fibroblasts - virology; Growth; Homeodomain Proteins - metabolism; Humans; Induced Pluripotent Stem Cells - pathology; Induced Pluripotent Stem Cells - physiology; Methodology; Mice; Nanog Homeobox Protein; Neurodegenerative Diseases - pathology; Octamer Transcription Factor-3 - metabolism; Physiological aspects; Postmortem Changes; Proteoglycans - metabolism; Skin - cytology; Stage-Specific Embryonic Antigens - metabolism; Stem cells
• DOI: 10.1186/2051-5960-2-4
• ISSN: 2051-5960

Induced pluripotent stem cells (iPSCs) derived from patients with neurodegenerative disease generally lack neuropathological confirmation, the gold standard for disease classification and grading of severity. The use of tissue with a definitive neuropathological diagnosis would be an ideal source for iPSCs. The challenge to this approach is that the majority of biobanked brain tissue was not meant for growing live cells, and thus was not frozen in the presence of cryoprotectants such as DMSO. We report the generation of iPSCs from frozen non-cryoprotected dural tissue stored at -80°C for up to 11 years. This autopsy cohort included subjects with Alzheimer's disease and four other neurodegenerative diseases. Disease-specific iPSCs can be generated from readily available, archival biobanked tissue. This allows for rapid expansion of generating iPSCs with confirmed pathology as well as allowing access to rare patient variants that have been banked.